DK0796260T3 - Rapamycin-42-oximer og -hydroxylaminer - Google Patents

Rapamycin-42-oximer og -hydroxylaminer

Info

Publication number: DK0796260T3
Authority: DK; Denmark
Prior art keywords: alkyl; independently; oxymers; hydroxylamines; rapamycin
Prior art date: 1994-12-07

Application number

DK95943018T

Other languages

Danish (da)

English (en)

Inventor

Amedeo Arturo Failli

Guy Alan Schiehser

Oleg Igorevich Bleyman

Original Assignee

American Home Prod

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-07

Filing date

1995-12-06

Publication date

2001-09-03

1995-12-06 Application filed by American Home Prod filed Critical American Home Prod

2001-09-03 Application granted granted Critical

2001-09-03 Publication of DK0796260T3 publication Critical patent/DK0796260T3/da

Links

150000002443 hydroxylamines Chemical class 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 3
HCUOEKSZWPGJIM-YBRHCDHNSA-N (e,2e)-2-hydroxyimino-6-methoxy-4-methyl-5-nitrohex-3-enamide Chemical compound COCC([N+]([O-])=O)\C(C)=C\C(=N/O)\C(N)=O HCUOEKSZWPGJIM-YBRHCDHNSA-N 0.000 abstract 1
101001109689 Homo sapiens Nuclear receptor subfamily 4 group A member 3 Proteins 0.000 abstract 1
101000598778 Homo sapiens Protein OSCP1 Proteins 0.000 abstract 1
101001067395 Mus musculus Phospholipid scramblase 1 Proteins 0.000 abstract 1
102100022673 Nuclear receptor subfamily 4 group A member 3 Human genes 0.000 abstract 1
125000003342 alkenyl group Chemical group 0.000 abstract 1
125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
125000000278 alkyl amino alkyl group Chemical group 0.000 abstract 1
125000000304 alkynyl group Chemical group 0.000 abstract 1
125000004103 aminoalkyl group Chemical group 0.000 abstract 1
230000000843 anti-fungal effect Effects 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
230000001028 anti-proliverative effect Effects 0.000 abstract 1
229940121375 antifungal agent Drugs 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
125000004432 carbon atom Chemical group C* 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000004966 cyanoalkyl group Chemical group 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
125000004985 dialkyl amino alkyl group Chemical group 0.000 abstract 1
125000003709 fluoroalkyl group Chemical group 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
230000001506 immunosuppresive effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
-1 trifluoromethylalkyl Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Oncology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

DK95943018T 1994-12-07 1995-12-06 Rapamycin-42-oximer og -hydroxylaminer DK0796260T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/350,557 US5563145A (en)	1994-12-07	1994-12-07	Rapamycin 42-oximes and hydroxylamines
PCT/US1995/015901 WO1996017845A1 (en)	1994-12-07	1995-12-06	Rapamycin 42-oximes and hydroxylamines

Publications (1)

Publication Number	Publication Date
DK0796260T3 true DK0796260T3 (da)	2001-09-03

Family

ID=23377241

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK95943018T DK0796260T3 (da)	1994-12-07	1995-12-06	Rapamycin-42-oximer og -hydroxylaminer

Country Status (21)

Country	Link
US (2)	US5563145A (de)
EP (1)	EP0796260B1 (de)
JP (1)	JPH10510270A (de)
KR (1)	KR100380870B1 (de)
CN (1)	CN1085212C (de)
AT (1)	ATE202357T1 (de)
AU (1)	AU714120B2 (de)
BR (1)	BR9509875A (de)
CA (1)	CA2206965A1 (de)
CZ (1)	CZ172097A3 (de)
DE (1)	DE69521438T2 (de)
DK (1)	DK0796260T3 (de)
ES (1)	ES2157353T3 (de)
GR (1)	GR3036209T3 (de)
HU (1)	HU223471B1 (de)
MX (1)	MX9704057A (de)
NZ (1)	NZ298639A (de)
PT (1)	PT796260E (de)
RU (1)	RU2172316C2 (de)
UA (1)	UA49815C2 (de)
WO (1)	WO1996017845A1 (de)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6515009B1 (en)	1991-09-27	2003-02-04	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en)	1993-01-28	1998-09-22	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en)	1993-01-28	1999-11-09	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en)	1993-05-13	2002-12-10	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US5780462A (en) *	1995-12-27	1998-07-14	American Home Products Corporation	Water soluble rapamycin esters
US5922730A (en) *	1996-09-09	1999-07-13	American Home Products Corporation	Alkylated rapamycin derivatives
US8790391B2 (en)	1997-04-18	2014-07-29	Cordis Corporation	Methods and devices for delivering therapeutic agents to target vessels
US6273913B1 (en) *	1997-04-18	2001-08-14	Cordis Corporation	Modified stent useful for delivery of drugs along stent strut
IT1293795B1 (it) *	1997-07-28	1999-03-10	Angelini Ricerche Spa	Farmaco attivo nel ridurre la produzione di proteina mcp-1
US20050031611A1 (en) *	1998-05-08	2005-02-10	Beth Israel Deaconess Medical Center	Transplant tolerance by costimulation blockade and T-cell activation-induced apoptosis
US6015809A (en) *	1998-08-17	2000-01-18	American Home Products Corporation	Photocyclized rapamycin
US6331547B1 (en)	1999-08-18	2001-12-18	American Home Products Corporation	Water soluble SDZ RAD esters
US7807211B2 (en) *	1999-09-03	2010-10-05	Advanced Cardiovascular Systems, Inc.	Thermal treatment of an implantable medical device
US6277983B1 (en)	2000-09-27	2001-08-21	American Home Products Corporation	Regioselective synthesis of rapamycin derivatives
TWI256395B (en) *	1999-09-29	2006-06-11	Wyeth Corp	Regioselective synthesis of rapamycin derivatives
US8236048B2 (en)	2000-05-12	2012-08-07	Cordis Corporation	Drug/drug delivery systems for the prevention and treatment of vascular disease
US20020013335A1 (en) *	2000-06-16	2002-01-31	American Home Products Corporation	Method of treating cardiovascular disease
EP1709974A3 (de) *	2000-06-16	2006-12-06	Wyeth	Verfahren zur behandlung von kardiovaskulären erkrankungen mit rapamycin
US6670355B2 (en)	2000-06-16	2003-12-30	Wyeth	Method of treating cardiovascular disease
ES2228932T3 (es)	2000-08-11	2005-04-16	Wyeth	Procedimiento de tratamiento del carcinoma positivo de estrogenos.
US6399625B1 (en)	2000-09-27	2002-06-04	Wyeth	1-oxorapamycins
AU9486901A (en)	2000-09-29	2002-04-08	Cordis Corp	Coated medical devices
US20070276473A1 (en) *	2000-09-29	2007-11-29	Llanos Gerard H	Medical Devices, Drug Coatings and Methods for Maintaining the Drug Coatings Thereon
US20060222756A1 (en) *	2000-09-29	2006-10-05	Cordis Corporation	Medical devices, drug coatings and methods of maintaining the drug coatings thereon
US20040018228A1 (en) *	2000-11-06	2004-01-29	Afmedica, Inc.	Compositions and methods for reducing scar tissue formation
US20040241211A9 (en) *	2000-11-06	2004-12-02	Fischell Robert E.	Devices and methods for reducing scar tissue formation
US6534693B2 (en) *	2000-11-06	2003-03-18	Afmedica, Inc.	Surgically implanted devices having reduced scar tissue formation
US20050084514A1 (en) *	2000-11-06	2005-04-21	Afmedica, Inc.	Combination drug therapy for reducing scar tissue formation
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US6613083B2 (en)	2001-05-02	2003-09-02	Eckhard Alt	Stent device and method
EP1419154B1 (de) *	2001-08-22	2005-10-05	Wyeth	Rapanycin29-enole
CA2455311A1 (en) *	2001-08-22	2003-03-06	Wyeth	Rapamycin dialdehydes
US8303651B1 (en)	2001-09-07	2012-11-06	Advanced Cardiovascular Systems, Inc.	Polymeric coating for reducing the rate of release of a therapeutic substance from a stent
BR0307544A (pt) *	2002-02-01	2004-12-07	Ariad Gene Therapeutics Inc	Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos
ES2296063T3 (es)	2002-07-16	2008-04-16	Biotica Technology Limited	Produccion de poliquetidos y otros productos naturales.
AU2003254168A1 (en)	2002-07-30	2004-02-16	Wyeth	Parenteral formulations containing a rapamycin hydroxyester
WO2004060283A2 (en)	2002-12-16	2004-07-22	Nitromed, Inc.	Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
US7160867B2 (en) *	2003-05-16	2007-01-09	Isotechnika, Inc.	Rapamycin carbohydrate derivatives
US20050118344A1 (en)	2003-12-01	2005-06-02	Pacetti Stephen D.	Temperature controlled crimping
ES2313328T3 (es) *	2004-04-14	2009-03-01	Wyeth	Procedimiento para la preparacion de 42-esteres de rapamicina y 32-esteres de fk-506 con acido dicarboxilico, precursores para conjugados de rapamicina y anticuerpos.
JP2007534337A (ja) *	2004-04-27	2007-11-29	ワイス	ラパマイシン特異的メチラーゼを用いるラパマイシンの標識
WO2006115509A2 (en)	2004-06-24	2006-11-02	Novartis Vaccines And Diagnostics Inc.	Small molecule immunopotentiators and assays for their detection
GB0417852D0 (en)	2004-08-11	2004-09-15	Biotica Tech Ltd	Production of polyketides and other natural products
WO2006050461A1 (en) *	2004-10-28	2006-05-11	Wyeth	Use of an mtor inhibitor in treatment of uterine leiomyoma
US8021849B2 (en) *	2004-11-05	2011-09-20	Siemens Healthcare Diagnostics Inc.	Methods and kits for the determination of sirolimus in a sample
GB0503936D0 (en)	2005-02-25	2005-04-06	San Raffaele Centro Fond	Method
GB0504994D0 (en)	2005-03-11	2005-04-20	Biotica Tech Ltd	Novel compounds
WO2006095173A2 (en)	2005-03-11	2006-09-14	Biotica Technology Limited	Medical uses of 39-desmethoxyrapamycin and analogues thereof
US20100061994A1 (en) *	2005-03-11	2010-03-11	Rose Mary Sheridan	Medical uses of 39-desmethoxyrapamycin and analogues thereof
US7189582B2 (en) *	2005-04-27	2007-03-13	Dade Behring Inc.	Compositions and methods for detection of sirolimus
EP2295080A3 (de)	2005-07-25	2011-06-22	Emergent Product Development Seattle, LLC	B-Zell-Verringerung mit CD37-spezifischen und CD20-spezifischen Bindungsmolekülen
BRPI0618042A2 (pt)	2005-11-04	2011-08-16	Wyeth Corp	usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
EP1962819A1 (de) *	2005-12-20	2008-09-03	Wyeth	Steuerung der formstabilität einer cci-779-dosierung durch steuerung der unreinheiten von wirkstoffen
GB0609963D0 (en) *	2006-05-19	2006-06-28	Biotica Tech Ltd	Novel compounds
GB0609962D0 (en) *	2006-05-19	2006-06-28	Biotica Tech Ltd	Novel compounds
US20080039362A1 (en) *	2006-08-09	2008-02-14	Afmedica, Inc.	Combination drug therapy for reducing scar tissue formation
US20080051691A1 (en) *	2006-08-28	2008-02-28	Wyeth	Implantable shunt or catheter enabling gradual delivery of therapeutic agents
US8998846B2 (en)	2006-11-20	2015-04-07	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US9700704B2 (en)	2006-11-20	2017-07-11	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US8414525B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8414526B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US9737640B2 (en)	2006-11-20	2017-08-22	Lutonix, Inc.	Drug releasing coatings for medical devices
US20080276935A1 (en)	2006-11-20	2008-11-13	Lixiao Wang	Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US20080175887A1 (en)	2006-11-20	2008-07-24	Lixiao Wang	Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8414910B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8425459B2 (en)	2006-11-20	2013-04-23	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
TW200845960A (en) *	2007-04-05	2008-12-01	Wyeth Corp	Wortmannin-rapalog conjugate and uses thereof
TW200901989A (en)	2007-04-10	2009-01-16	Wyeth Corp	Anti-tumor activity of CCI-779 in papillary renal cell cancer
US20100048524A1 (en)	2008-03-14	2010-02-25	Angela Brodie	Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
EP2278966B1 (de)	2008-03-21	2019-10-09	The University of Chicago	Behandlung mit opioid-antagonisten und mtor-inhibitoren
PT2132228E (pt)	2008-04-11	2011-10-11	Emergent Product Dev Seattle	Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
WO2010024898A2 (en)	2008-08-29	2010-03-04	Lutonix, Inc.	Methods and apparatuses for coating balloon catheters
PT2365802T (pt)	2008-11-11	2017-11-14	Univ Texas	Microcápsulas de rapamicina e utilização para o tratamento de cancro
WO2010091306A1 (en)	2009-02-05	2010-08-12	Tokai Pharmaceuticals	Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
CA2777128A1 (en)	2009-10-30	2011-05-05	Ariad Pharmaceuticals, Inc.	Methods and compositions for treating cancer
US20170079962A1 (en)	2009-11-11	2017-03-23	Rapamycin Holdings, Llc	Oral Rapamycin Preparation and Use for Stomatitus
US9283211B1 (en)	2009-11-11	2016-03-15	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
JP2013521002A (ja)	2010-03-05	2013-06-10	プレジデントアンドフェロウズオブハーバードカレッジ	誘導樹状細胞組成物及びその使用
MX342590B (es)	2010-04-27	2016-10-05	Roche Glycart Ag	Terapia de combinacion de un anticuerpo cd20 afucosilado con un inhibidor mtor.
JP2014519813A (ja)	2011-04-25	2014-08-21	オーエスアイ・ファーマシューティカルズ，エルエルシー	癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
EP2532740A1 (de)	2011-06-11	2012-12-12	Michael Schmück	Antigenspezifische CD4+ und CD8+ zentrale Gedächtnis-T-Zellpräparate für adoptive T-Zelltherapie
GB201122305D0 (en)	2011-12-23	2012-02-01	Biotica Tech Ltd	Novel compound
WO2014059295A1 (en)	2012-10-12	2014-04-17	The Board Of Regents Of The University Of Texas System	Use of mtor inhibitors to treat vascular cognitive impairment
WO2014068070A1 (en)	2012-10-31	2014-05-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for preventing antiphospholipid syndrome (aps)
WO2014160328A1 (en)	2013-03-13	2014-10-02	The Board Of Regents Of The University Of Texas System	Mtor inhibitors for prevention of intestinal polyp growth
EP2968370A4 (de)	2013-03-14	2016-09-21	Univ Maryland	Mittel zur androgenrezeptor-abwärtsregelung und verwendungen davon
EP3033088A4 (de)	2013-08-12	2017-03-08	Tokai Pharmaceuticals, Inc.	Biomarker zur behandlung neoplastischer störungen mit androgen-anzielenden therapien
AU2014373683B2 (en)	2013-12-31	2020-05-07	Rapamycin Holdings, Llc	Oral rapamycin nanoparticle preparations and use
US9700544B2 (en)	2013-12-31	2017-07-11	Neal K Vail	Oral rapamycin nanoparticle preparations
WO2015149001A1 (en)	2014-03-27	2015-10-01	The Brigham And Women's Hospital, Inc.	Metabolically-activated drug conjugates to overcome resistance in cancer therapy
CN106659758A (zh)	2014-06-02	2017-05-10	儿童医疗中心有限公司	用于免疫调节的组合物和方法
WO2016040806A1 (en)	2014-09-11	2016-03-17	The Regents Of The University Of California	mTORC1 INHIBITORS
WO2017029391A1 (en)	2015-08-20	2017-02-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	New method for treating cancer
JP2020507632A (ja)	2017-02-10	2020-03-12	マウントタムセラピューティクス, インコーポレイテッドMount Tam Therapeutics, Inc.	ラパマイシン類似体
EP3848065B1 (de)	2017-05-15	2023-07-26	C. R. Bard, Inc.	Medizinische vorrichtung mit wirkstofffreisetzender beschichtung und zwischenschicht
WO2019002168A1 (en)	2017-06-26	2019-01-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING OLMSTED SYNDROME
WO2019012024A1 (en)	2017-07-13	2019-01-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	METHODS FOR INCREASING EXPANSION AND IMMUNOSUPPRESSIVE CAPACITY OF A CD8 + CD45RCBAS TREGS POPULATION / -
CA3098698A1 (en)	2018-05-01	2019-11-07	Revolution Medicines, Inc.	C26-linked rapamycin analogs as mtor inhibitors
CN118978535A (zh)	2018-05-01	2024-11-19	锐新医药公司	作为mTOR抑制剂的C40-、C28-及C-32连接的雷帕霉素类似物
CN113164557A (zh)	2018-07-23	2021-07-23	因柯利尔疗法公司	治疗神经性病症的方法
CA3107349A1 (en)	2018-07-23	2020-01-30	Enclear Therapies, Inc.	Methods of treating neurological disorders
EP3849545A1 (de)	2018-09-10	2021-07-21	Institut National de la Santé et de la Recherche Médicale (INSERM)	Verfahren zur behandlung von neurofibromatose
JP7262581B2 (ja)	2018-11-14	2023-04-21	ルトニックス，インコーポレーテッド	改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
US12594275B2 (en)	2019-02-07	2026-04-07	The Regents Of The University Of California	Immunophilin binding agents and uses thereof
JP7487228B2 (ja)	2019-04-08	2024-05-20	バード・ペリフェラル・バスキュラー・インコーポレーテッド	改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
WO2020210634A1 (en)	2019-04-11	2020-10-15	Enclear Therapies, Inc.	Methods of amelioration of cerebrospinal fluid and devices and systems therefor
IL301751A (en)	2020-09-29	2023-05-01	Enclear Therapies Inc	Subarachnoid fluid management method and system
JP2024529341A (ja)	2021-07-15	2024-08-06	プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ	粒子が付着している細胞に関連する組成物および方法
JP2025522296A (ja)	2022-05-25	2025-07-15	レヴォリューション・メディスンズ，インコーポレイテッド	ｍＴＯＲ阻害剤によりがんを処置する方法
JP2025521677A (ja)	2022-07-06	2025-07-10	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	増殖性糸球体腎炎を処置するための方法
US20260060969A1 (en)	2022-08-04	2026-03-05	Institut National de la Santé et de la Recherche Médicale	Methods for the treatment of lymphoproliferative disorders
GB202415232D0 (en)	2024-10-16	2024-11-27	Nacamed As	Composition

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA737247B (en) *	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US3993749A (en) *	1974-04-12	1976-11-23	Ayerst Mckenna And Harrison Ltd.	Rapamycin and process of preparation
US4885171A (en) *	1978-11-03	1989-12-05	American Home Products Corporation	Use of rapamycin in treatment of certain tumors
US4316885A (en) *	1980-08-25	1982-02-23	Ayerst, Mckenna And Harrison, Inc.	Acyl derivatives of rapamycin
US4401653A (en) *	1981-03-09	1983-08-30	Ayerst, Mckenna & Harrison Inc.	Combination of rapamycin and picibanil for the treatment of tumors
US4375464A (en) *	1981-11-19	1983-03-01	Ayerst, Mckenna & Harrison Inc.	Antibiotic AY24,668 and process of preparation
US4650803A (en) *	1985-12-06	1987-03-17	University Of Kansas	Prodrugs of rapamycin
US5100899A (en) *	1989-06-06	1992-03-31	Roy Calne	Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5023264A (en) *	1990-07-16	1991-06-11	American Home Products Corporation	Rapamycin oximes
US5023263A (en) *	1990-08-09	1991-06-11	American Home Products Corporation	42-oxorapamycin
US5023262A (en) *	1990-08-14	1991-06-11	American Home Products Corporation	Hydrogenated rapamycin derivatives
US5130307A (en) *	1990-09-28	1992-07-14	American Home Products Corporation	Aminoesters of rapamycin
US5221670A (en) *	1990-09-19	1993-06-22	American Home Products Corporation	Rapamycin esters
US5233036A (en) *	1990-10-16	1993-08-03	American Home Products Corporation	Rapamycin alkoxyesters
US5080899A (en) *	1991-02-22	1992-01-14	American Home Products Corporation	Method of treating pulmonary inflammation
US5078999A (en) *	1991-02-22	1992-01-07	American Home Products Corporation	Method of treating systemic lupus erythematosus
US5120842A (en) *	1991-04-01	1992-06-09	American Home Products Corporation	Silyl ethers of rapamycin
IL101353A0 (en) *	1991-04-03	1992-11-15	American Home Prod	Pharmaceutical compositions for treating diabetes
US5100883A (en) *	1991-04-08	1992-03-31	American Home Products Corporation	Fluorinated esters of rapamycin
US5118678A (en) *	1991-04-17	1992-06-02	American Home Products Corporation	Carbamates of rapamycin
US5194447A (en) *	1992-02-18	1993-03-16	American Home Products Corporation	Sulfonylcarbamates of rapamycin
US5091389A (en) *	1991-04-23	1992-02-25	Merck & Co., Inc.	Lipophilic macrolide useful as an immunosuppressant
US5138051A (en) *	1991-08-07	1992-08-11	American Home Products Corporation	Rapamycin analogs as immunosuppressants and antifungals
US5102876A (en) *	1991-05-07	1992-04-07	American Home Products Corporation	Reduction products of rapamycin
US5118677A (en) *	1991-05-20	1992-06-02	American Home Products Corporation	Amide esters of rapamycin
US5169851A (en) *	1991-08-07	1992-12-08	American Home Products Corporation	Rapamycin analog as immunosuppressants and antifungals
US5151413A (en) *	1991-11-06	1992-09-29	American Home Products Corporation	Rapamycin acetals as immunosuppressant and antifungal agents
US5177203A (en) *	1992-03-05	1993-01-05	American Home Products Corporation	Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
ZA935110B (en) *	1992-07-17	1994-02-04	Smithkline Beecham Corp	Rapamycin derivatives
AU4812393A (en) *	1992-09-03	1994-03-29	Biochem Pharma Inc.	Use of rapamycin in the treatment of aids
US5302584A (en) *	1992-10-13	1994-04-12	American Home Products Corporation	Carbamates of rapamycin
US5260300A (en) *	1992-11-19	1993-11-09	American Home Products Corporation	Rapamycin carbonate esters as immuno-suppressant agents
US5378836A (en) *	1993-10-08	1995-01-03	American Home Products Corporation	Rapamycin oximes and hydrazones
US5373014A (en) *	1993-10-08	1994-12-13	American Home Products Corporation	Rapamycin oximes
US5385910A (en) *	1993-11-22	1995-01-31	American Home Products Corporation	Gem-distributed esters of rapamycin
US5385908A (en) *	1993-11-22	1995-01-31	American Home Products Corporation	Hindered esters of rapamycin
US5385909A (en) *	1993-11-22	1995-01-31	American Home Products Corporation	Heterocyclic esters of rapamycin

1994
- 1994-12-07 US US08/350,557 patent/US5563145A/en not_active Expired - Lifetime
1995
- 1995-12-06 KR KR1019970703753A patent/KR100380870B1/ko not_active Expired - Fee Related
- 1995-12-06 WO PCT/US1995/015901 patent/WO1996017845A1/en not_active Ceased
- 1995-12-06 CN CN95197475A patent/CN1085212C/zh not_active Expired - Fee Related
- 1995-12-06 PT PT95943018T patent/PT796260E/pt unknown
- 1995-12-06 MX MX9704057A patent/MX9704057A/es not_active IP Right Cessation
- 1995-12-06 JP JP8517769A patent/JPH10510270A/ja not_active Withdrawn
- 1995-12-06 NZ NZ298639A patent/NZ298639A/xx unknown
- 1995-12-06 DK DK95943018T patent/DK0796260T3/da active
- 1995-12-06 AT AT95943018T patent/ATE202357T1/de not_active IP Right Cessation
- 1995-12-06 DE DE69521438T patent/DE69521438T2/de not_active Expired - Fee Related
- 1995-12-06 EP EP95943018A patent/EP0796260B1/de not_active Expired - Lifetime
- 1995-12-06 CA CA002206965A patent/CA2206965A1/en not_active Abandoned
- 1995-12-06 AU AU44176/96A patent/AU714120B2/en not_active Ceased
- 1995-12-06 RU RU97111872/04A patent/RU2172316C2/ru not_active IP Right Cessation
- 1995-12-06 BR BR9509875A patent/BR9509875A/pt not_active IP Right Cessation
- 1995-12-06 UA UA97073588A patent/UA49815C2/uk unknown
- 1995-12-06 ES ES95943018T patent/ES2157353T3/es not_active Expired - Lifetime
- 1995-12-06 HU HU9701907A patent/HU223471B1/hu not_active IP Right Cessation
- 1995-12-06 CZ CZ971720A patent/CZ172097A3/cs unknown
1996
- 1996-05-30 US US08/655,424 patent/US5677295A/en not_active Expired - Lifetime
2001
- 2001-07-11 GR GR20010401062T patent/GR3036209T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
KR100380870B1 (ko)	2003-10-04
ATE202357T1 (de)	2001-07-15
AU714120B2 (en)	1999-12-16
EP0796260B1 (de)	2001-06-20
WO1996017845A1 (en)	1996-06-13
DE69521438T2 (de)	2002-05-16
JPH10510270A (ja)	1998-10-06
ES2157353T3 (es)	2001-08-16
CA2206965A1 (en)	1996-06-13
CN1085212C (zh)	2002-05-22
MX9704057A (es)	1997-08-30
NZ298639A (en)	1999-11-29
BR9509875A (pt)	1997-09-30
GR3036209T3 (en)	2001-10-31
HUT77141A (hu)	1998-03-02
DE69521438D1 (de)	2001-07-26
AU4417696A (en)	1996-06-26
RU2172316C2 (ru)	2001-08-20
US5563145A (en)	1996-10-08
HU223471B1 (hu)	2004-07-28
HK1002361A1 (en)	1998-08-21
UA49815C2 (uk)	2002-10-15
CN1174554A (zh)	1998-02-25
US5677295A (en)	1997-10-14
CZ172097A3 (cs)	1998-01-14
EP0796260A1 (de)	1997-09-24
PT796260E (pt)	2001-09-28

Publication	Publication Date	Title
BR9509875A (pt)	1997-09-30	Oximas-42 de rapamicina e hidroxilaminas
DK0730598T3 (da)	1999-11-15	Hindrede estere af rapamycin samt deres anvendelse som lægemidler
ES2154720T3 (es)	2001-04-16	Esteres heterociclicos de la rapamicina y composiciones farmaceuticas que los contienen.
GR3036712T3 (en)	2001-12-31	Hindered n-oxide esters of rapamycin and their use as medicaments
ZA9610315B (en)	1997-06-17	Naphthyl-substituted benzimidazole derivates as anti-coagulants
CO5280078A1 (es)	2003-05-30	Compuestos
ATE175661T1 (de)	1999-01-15	Benzamid-derivate als vasopressin-antagonisten
MY117092A (en)	2004-05-31	Chemotherapeutic pyrrolocarbazole derivatives
ES2177583T3 (es)	2002-12-16	Nuevo compuesto tetraciclico.
DK0655065T3 (de)	1997-02-24
CA2333038A1 (en)	1999-12-02	Sleep-inducing preparation
NO891949D0 (no)	1989-05-16	Fremgangsmaate for fremstilling av terapeutisk aktive pyrimidindionforbindelser.
DE3360904D1 (de)	1985-11-07	A fungicidal indanylbenzamide
ATE176906T1 (de)	1999-03-15	Benzolactam-derivate
CA2111955A1 (en)	1993-11-11	Novel tetracyclic compound
TW334428B (en)	1998-06-21	Novel benzodiazepine derivatives
EA199900684A1 (ru)	2000-04-24	Производные иминоазаантрациклинона для лечения амилоидоза
CA2123890A1 (en)	1994-03-03	Novel Sulfonic Acid Derivative and Medicinal Use Thereof
ES467744A1 (es)	1979-09-01	Un procedimiento para preparar un fungicida que contiene sa-les organicas de amonio cuaternario
ECSP951498A (es)	1996-12-13	Nuevos derivados de pirrocarbazol case ran 4121/15
MY109672A (en)	1997-04-30	Azole compounds, their production and use